Taking oestradiol therapy within 6 years after the start of menopause significantly delayed lipid plaque buildup in arterial walls — a leading cause of atherosclerosis, but such benefit was not seen when starting oestradiol a decade after menopause, reveals a secondary analysis of the ELITE* study presented at the recent EPI Lifestyle 2020 Scientific Sessions.
Dr. Hang Wun Raymond Li, Prof. Pak-Chung Ho, Dr. Ernest Hung Yu Ng, 20200317000000
Anti-Müllerian hormone (AMH) was initially recognized as the factor that
determines regression of the Müllerian duct in the male foetus and
hence plays an important role in male sex differentiation. Production of
AMH in adult women was first reported in 1990.1 In the past two
decades, its role in female ovarian function and the clinical utilities
of serum AMH level has been increasingly studied.
Dr. Daniel Chan, Assoc Prof. Daisy Kwai-Lin Chan, 20200312000000
Hypoglycaemia is one of the most common clinical issues facing newborn
babies. It can be caused by abnormalities in the glycogen stores,
alternative substrates, and/or functioning enzymes. The definition of
neonatal hypoglycaemia itself remains challenging. Understanding normal
glucose physiology and biochemistry is important so that the
neonatologist can initiate appropriate investigations to elucidate an
aetiology and institute correct management. Early diagnosis and prompt
treatment of hypoglycaemia will reduce the risk of brain injury to the
Women with shorter reproductive years and higher parity are at much greater risk of cognitive impairment in late life, although use of oral contraceptives and hormone replacement therapy (HRT) may mitigate this risk, according to a study from Singapore.
A mobile-based screening application (app) has been shown to increase postpartum compliance rates and improve the diagnosis of type 2 diabetes mellitus (T2DM) among women with gestational diabetes, reports a recent study.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.